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Purpose: The aim of this study was to compare cure rates and complications of poly-
dimethylsiloxane (Macroplastique
Ⓡ) and dextranomer/hyaluronic acid copolymer 
(Deflux
Ⓡ) in the treatment of vesicoureteral reflux (VUR).
Materials and Methods: From April 2001 to March 2008, 29 boys and 42 girls (total of 
115 ureters) with a mean age of 6 years who had undergone endoscopic subureteral 
transurethral injection for VUR were enrolled. A single subureteral injection of 
Macroplastique was performed in 31 ureters in 23 children (group I; grade II: 4; grade 
III: 12; grade IV: 9; grade V: 6), and a single subureteral injection of Deflux was per-
formed in 84 ureters in 48 children (group II; grade II: 24; grade III: 14; grade IV: 25; 
grade V: 21). Renal ultrasound was done 1 day after injection, and voiding cystour-
ethrography (VCUG) was done at 3 months. Successful reflux correction was defined 
as absent or grade I reflux on follow-up VCUG.
Results: No significant difference in success rates was observed between group I and 
group II [80.6% (25/31) vs. 78.6% (66/84), respectively, p＞0.05]. The following post-
operative complications developed: ureteral obstruction in 2 ureters of group I and 3 
ureters of group II, asymptomatic urinary tract infection in 3 patients of group I and 
2 patients of group II, and bladder calcification by erosion or mucosal necrosis in 2 pa-
tients of group I.
Conclusions: Despite differences in material properties, both Macroplastique and 
Deflux were safe for the treatment of children with VUR. Because of the risk of bladder 
mucosal necrosis and substantial decreases in volume after implantation, long-term 
follow-up is required.
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In recent years, endoscopic subureteral transurethral in-
jection (STING) has become a first-line therapy for children 
with vesicoureteral reflux (VUR) because of its high suc-
cess rates and few complications [1].
　Debate over the ideal bulking agent in endoscopic ther-
apy for children with VUR remains controversial, however 
[2,3]. The substance should be nontoxic, biocompatible, 
nonmigratory, and nonantigenic and should cause mini-
mal local inflammation. Many bulking agents have been 
used to treat reflux, including polytetrafluoroethylene, col-
lagen, autologous injectables, polydimethylsiloxane (Ma-
croplastique
Ⓡ; Uroplasty, Minnetonka, USA), and dextra-
nomer/hyaluronic acid copolymer (Deflux
Ⓡ; Oceana The-
rapeutics, Inc, Edison, USA).
　Among these agents, Macroplastique is one of the most 
popular bulking agents and is used extensively in medical 
applications. Macroplastique, a nonbiodegradable sub-
stance, is reabsorbed and exchanged with a reactive tran-
sudate containing fibroblasts that then facilitate its 
encapsulation. Deflux was introduced in 1995 by Stenberg 
and Läckgren [4] and was approved by the Food and Drug 
Administration in 2001 as an acceptable implant for sub-Korean J Urol 2010;51:128-131
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TABLE 1. Results of endoscopic subureteral injection of Macroplas-





















Total  25/31 (80.6) 66/84 (78.6) 0.808
ureteral injection for VUR in children. Deflux represents 
a new biocompatible material without immunogenic prop-
erties and a lack of distant migration. Previous studies in-
dicated high success rates of 68% to 90% with endoscopic 
injection using Macroplastique or Deflux [5-7].
　This is the first study by a single surgeon in Korea to com-
pare outcomes and complications of these two agents for en-
doscopic treatment of VUR in children.
MATERIALS AND METHODS
Between April 2001 and March 2008, 71 children (29 boys 
and 42 girls; 115 ureters) who underwent endoscopic sub-
ureteral injection with Macroplastique (from April 2001 to 
February 2004) or Deflux (from March 2004 to March 2008) 
for VUR were retrospectively evaluated.
　Families were provided with information reflecting our 
current knowledge of VUR management. All families were 
counseled regarding the natural history of VUR with re-
spect to resolution rates, based on grade of VUR, and the 
risks and benefits of antibiotic use, open surgery, and sub-
ureteral injection therapy [8]. All patients underwent pre-
operative renal and bladder ultrasonography, voiding cys-
tourethrography (VCUG), and dimercapto-succinic acid 
(DMSA) renal scans. Reflux grades were evaluated accord-
ing to the reflux grading system recommended by the 
International Reflux Study [9]. The indications for surgery 
included breakthrough infections during antibiotic pro-
phylaxis, renal scarring, and persistent reflux. Exclusion 
criteria included duplicated refluxing ureters, neurogenic 
bladder determined by history, and failed surgical reim-
plantation.
　The children’s mean age was 6.2 years (range, 1.2-10.5 
years). The mean period of follow-up was 26 months (range, 
12-42 months). A single subureteral injection of Macro-
plastique (group I) was performed in 23 children (31 ure-
ters; grade II: 4; grade III: 12; grade IV: 9; grade V: 6), and 
Deflux (group II) was used in 48 children (84 ureters; grade 
II: 24; grade III: 14; grade IV: 25; grade V: 21).
　All procedures were performed by a single operator with 
the children in the lithotomy position under general 
anesthesia. Ureteral orifices were visualized by using a 9.5 
Fr Wolf pediatric cystoscope. The 3.7 Fr needle was placed 
within the submucosa of the ureter at the 6 o’clock position, 
and Macroplastique or Deflux was injected inside the lu-
men of the ureter until an adequate subureteric mound was 
attained [10]. The mean amount of each substance injected 
into the ureter was 1.1 ml (range, 0.5-1.5 ml) in group I and 
1.3 ml (range, 0.5-2.0 ml) in group II. The amount of each 
substance injected into the ureter was determined accord-
ing to reflux grade or shape of the ureteral orifice.
　Renal ultrasonography for detection of urinary ob-
struction was performed 1 day after injection. All patients 
were discharged 1 day after the operation. All patients un-
derwent VCUG, ultrasonography, and urine culture from 
3 months after discharge. Thereafter, basic laboratory 
studies (complete blood count with differential count, blood 
urea nitrogen, creatinine, urine analysis, gram stain, and 
culture) and renal ultrasonography were followed up 
annually. Follow-up VCUG was performed in children 
with recurrent urinary tract infection or newly developed 
hydronephrosis. Successful reflux correction was defined 
as absent or grade I reflux on follow-up VCUG [11].
　Statistical analysis was performed by using SPSS stat-
istical software, version 13.0 (SPSS Inc, Chicago, USA). 
Chi-square tests were used for data analysis. A value of 
p-value＜0.05 was considered significant.
RESULTS
No significant difference in baseline characteristics (mean 
age, gender, reflux grade) were observed between group I 
and group II. The overall success rate after a single in-
jection was 80.6% (25 of 31) for group I. VUR disappeared 
in 75.0% (3 of 4) for grade II, 75.0% (9 of 12) for grade III, 
88.9% (8 of 9) for grade IV, and 83.3% (5 of 6) for grade V. 
Persistent grade I reflux was found in 1 patient. The suc-
cess rate of group II was 78.6% (66/84). VUR disappeared 
in 87.5% (21/24) for grade II, 78.6% (11/14) for grade III, 
84.0% (21/25) for grade IV, and 61.9% (13/21) for grade V. 
Persistent grade I reflux was found in 2 patients. There was 
no significant difference in cure rates between the two 
groups (p＞0.05) (Table 1).
　No intraoperative complications were noted. Postoper-
ative ureteral obstruction was found in 2 patients (6.4%) 
after Macroplastique injection and in 3 patients (3.6%) af-
ter Deflux injection. Postoperative obstruction was diag-
nosed by renal ultrasonography 1 day after injection. 
Children with postoperative ureteral obstruction had 
symptoms that included flank pain, elevated creatinine 
levels, and aggravated or newly developed hydrone-
phrosis. Following Deflux injection for bilateral VUR, one 
child required percutaneous ureteral stent placement, due 
to postoperative ureteral obstruction with serum crea-
tinine level elevation, whereas others required no inter-
vention. Following ureteral stent placement, the serum 
creatinine level decreased and hydronephrosis disap-
peared. We placed a percutaneous ureteral stent for 12 
days and removed it after the hydronephrosis disappeared 
on follow-up renal ultrasonography.
　Three (9.6%) patients in group I and two (2.4%) patients Korean J Urol 2010;51:128-131
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in group II had postoperative asymptomatic urinary tract 
infection during the follow-up period after successful in-
jection therapy. These patients showed no recurrence of re-
flux on follow-up VCUG, nor did they show newly developed 
renal cortical defects on the DMSA renal scan.
　Bladder calcification due to Macroplastique exposure 
from bladder mucosal necrosis or erosion was found in two 
patients at the 30- and 36-month follow-ups, and one pa-
tient underwent endoscopic removal.
DISCUSSION
The concept of subureteral injection was introduced by 
O’Donnell and Puri in the 1980s to create a less invasive 
treatment for VUR [12]. Endoscopic treatment is based on 
the principle of creating a solid support behind the intra-
vesical ureter and elongating the intramural length of the 
ureter [13]. Many studies have reported that endoscopic 
treatment is effective and safe as a first-line therapy for 
VUR; however, the ideal agent has not yet been identified 
[14,15].
　In 2002, Oswald et al reported on a comparison of a single 
endoscopic STING of Macroplastique versus Deflux for 
treatment of VUR in children [11]. Reflux was corrected in 
86.2% of the Macroplastique group and in 71.4% of the 
Deflux group at the 3-month follow-up visit. Reflux correc-
tion was maintained in 80.9% of the Macroplastique group 
and in 67.6% of the Deflux group at 1 year of follow-up. No 
postoperative complications were observed in either 
group. Our success rate, 80.3% of group I and 78.6% of group 
II, is consistent with these data. Also, there were no sig-
nificant differences in cure rate between the grades in the 
two groups (p＞0.05). The success rate for grade V of group 
II was lower than that of group I (61.9% vs. 83.3%). 
However, the success rate was increased up to 67.8% after 
the second injection in group II.
　Previous studies have indicated success rates of 70% to 
90% by endoscopic injection using Macroplastique, and a 
recent meta-analysis reported a success rate of 76.6% [15]. 
Studies to date have demonstrated single-injection cure 
rates from 68% to 86.1% with endoscopic injection using 
Deflux [7,14,16]; however, long-term follow-up studies us-
ing Deflux show that its long-term success rate is less than 
that of Macroplastique.
　Rates of local complications after the injection of endo-
scopic bulking agents are remarkably low. In particular, 
ureteral obstruction occurred in less than 1% of injected 
ureters using Macroplastique [17]. In our study, one child 
(1.2%) required percutaneous ureteral stent placement af-
ter Deflux injection for bilateral VUR. The rate of ureteral 
obstruction in our study is consistent with published data.
　In an earlier study, Puri and Guiney described a series 
of 11 patients with neurogenic bladder, one of whom devel-
oped new hydronephrosis after the injection [18]. This pa-
tient also had a dysmorphic-appearing ureter on pre-
operative imaging. A decade later, Misra et al retro-
spectively reviewed their experiences with 51 children (69 
ureters) with neurogenic bladder, one of whom (2%) devel-
oped ureteral obstruction requiring reimplantation [19]. 
Al-Hunayan et al observed a single case of symptomatic ob-
struction following polydimethylsiloxane injection [17]. 
However, they noted that an “excess amount” of substrate 
was injected in this case, and the obstruction was attrib-
uted to this factor. No further risk factors were identified. 
The injected Deflux volume was 3 ml in each ureter in the 
child with ureteral obstruction. 
　Bladder calcification due to Macroplastique exposure 
from bladder mucosal necrosis or erosion was found in 2 pa-
tients at 30 and 36 months of follow-up. Children with blad-
der calcification had microscopic hematuria. Because 
Macroplastique is a nonbiodegradable substance, the risk 
of bladder calcification is increased after correction be-
cause of the increased pressure and diminished perfusion 
of the overlying mucosa [20]. On the other hand, animal 
studies have demonstrated formation of a well-encapsu-
lated foreign body reaction at the injection site, composed 
of giant cells, fibroblasts, and collagen, with no substantial 
risk of migration [21]. Development of bladder mucosal ne-
crosis from Deflux exposure is also a possibility; however, 
because of the biodegradable nature of Deflux, sponta-
neous healing may occur. Long-term follow-up of patients 
injected with Macroplastique is required because of the 
risk of bladder mucosal necrosis. 
　To the best of our knowledge, we have reported on the 
first trial in Korea to compare two different bulking agents 
with regard to success rates and complications. However, 
several limitations of this study merit discussion. First, 
this study was not a prospective, randomized trial because 
of different introduction times for bulking agents in Korea. 
The success rate of STING with each bulking agent may 
have been affected by surgical technique before achieve-
ment of the learning curve because is the procedure was 
performed by a single surgeon. Second, we did not perform 
additional VCUG after successful injection therapy, other 
than for patients with asymptomatic urinary tract in-
fection and bladder calcification. Deflux is a biodegradable 
material and, in animal studies, hydrolysis of dextranomer 
microspheres has been identified as the likely cause of de-
creased implant volume [22]. Because microspheres con-
stitute 50% of the volume of Deflux, substantial decreases 
in volume after implantation may be anticipated. Howev-
er, ingrowth of fibroblasts and production of endogenous 
collagen between microspheres appeared to occur, thus 
stabilizing implant volume, and the 12 month volume re-
duction in rats was 23% [22]. Such volume stability un-
doubtedly has an important role in maintaining the 
long-term efficacy of Deflux in humans [7].
CONCLUSIONS
Cure rates and complication rates did not differ sig-
nificantly between Macroplastique and Deflux after a sin-
gle endoscopic subureteral injection. Both Macroplas-
tique and Deflux were safe materials for the treatment of Korean J Urol 2010;51:128-131
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VUR with few complications. However, long-term fol-
low-up of patients injected with Macroplastique and 
Deflux is required because of the risk of bladder mucosal 
necrosis and substantial decreases in volume after 
implantation.
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